WCO classification path
- Chapter30Pharmaceutical products
- Heading3002Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and ether similar products; cell cultures, whether or not modified
- Subheading300215Immunological products, put up in measured doses or in forms or packings for retail sale
- National30021500Immunological products, put up in measured doses or in forms or packings for retail sale
30021500
"Immunological products, put up in measured doses or in forms or packings for retail sale"
HS code 3002150000 (Chapter 30 "Pharmaceutical products"; Heading 3002 "Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and ether similar products; cell cultures, whether or not modified"; Subheading 300215 "Immunological products, put up in measured doses or in forms or packings for retail sale") under the Korea tariff schedule classifies "Immunological products, put up in measured doses or in forms or packings for retail sale". Korea customs apply MFN rate of 0, WTO bound rate 0. Statutory unit of measure: EA/KG. This commodity is subject to 1 import regulation or restriction; see compliance section below. 31 free trade agreement preferential rates are available for this code.
Tariff Schedule
| Classification | Rate |
|---|---|
MFN 税率 MFN rate | 0 |
WTO 约束税率 WTO bound rate | 0 |
FTA Preferential Rates
31 agreements available · certificate of origin required
| Agreement | Rate |
|---|---|
| AKFTA (ASEAN-Korea) | 0% |
| KAFTA (Korea-Australia) | 0% |
| CKFTA (Canada-Korea) / CPTPP | 0% |
| Korea-Central America (Costa Rica) | 0% |
| Korea-Central America (Honduras) | 0% |
| Korea-Central America (Nicaragua) | 0% |
| Korea-Central America (Panama) | 0% |
| Korea-Central America (El Salvador) | 0% |
| Korea-Chile | 0% |
| Korea-China | 0% |
| Korea-Colombia | 0% |
| Korea-EFTA | 0% |
| Korea-EU | 0% |
| Korea-UK | 0% |
| Korea-Indonesia (CEPA) | 0% |
| Korea-Israel | 0% |
| Korea-India (CEPA) | 0% |
| Korea-Cambodia | 0% |
| Korea-New Zealand | 0% |
| Korea-Peru | 0% |
| Korea-Philippines | 0% |
| RCEP (ASEAN) | 0% |
| RCEP (Australia) | 0% |
| RCEP (China) | 0% |
| RCEP (Japan) | 0% |
| RCEP (New Zealand) | 0% |
| Korea-Singapore | 0% |
| Korea-Turkey | 0% |
| KORUS (Korea-US) | 0% |
| Korea-Vietnam | 0% |
| RCEP | 0% |
Compliance & Controls
1 import regulation, restriction, or permit requirement
약사법
표준통관예정보고서(의약품등)
Global Benchmark
→ China export · Full 13-country compareHS-6 prefix 3002.15 across other jurisdictions